DOCSLIB.ORG

Products Containing Methylcobalamin for the Treatment of Multiple Sclerosis Or Other Demyelinating Conditions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Products Containing Methylcobalamin for the Treatment of Multiple Sclerosis Or Other Demyelinating Conditions * — II 1 1 INI II II 1 1 II 1 1 II I Mil II I II OJII Eur°Pean Patent Office <*S Office europeen des brevets (11) EP 0 835 660 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51 ) |nt. CI.6: A61 K 31 170 15.04.1998 Bulletin 1998/16 // (A61 K31/70, 31 :535) (21) Application number: 96870130.0 (22) Date of filing : 1 4.1 0.1 996 (84) Designated Contracting States: (72) Inventor: AT BE CH DE DK ES Fl FR GB GR IE IT LI LU MC Merckx, Gaston Edmond Filomena NL PT SE 2650 Edegem (BE) Designated Extension States: AL LT LV SI (74) Representative: Van Reet, Joseph et al (71) Applicant: Gevers Patents S. A., Merckx, Gaston Edmond Filomena Brussels Airport Business Park, 2650 Edegem (BE) Holidaystraat 5 1831 Diegem (BE) (54) Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions (57) Products containing methylcobalamin in an overdose corresponding to a weekly intramuscular dose higher than 1000 micrograms, preferably higher than 1 200 micrograms and corresponding more preferably to a weekly intramuscular dose of at least 1500 micro- grams, and an antidepressant enhancing the serotonin level as a combined preparation for simultaneous, sep- arate or sequential use in the treatment of multiple scle- rosis or other demyelinating conditions. < O CO CO LO CO CO o Q_ LU Printed by Xerox (UK) Business Services 2.16.1/3.4 1 EP 0 835 660 A1 Description An object of the present invention is therefore to provide a treatment of MS whereby not only the myelin The present invention relates to products contain- reconstructing effects of methylcobalamin overdoses ing methylcobalamin for the treatment of multiple sclero- can be improved but whereby the motor ability can fur- sis (MS) or other demyelinating conditions. s ther be achieved and wherein especially the observed Multiple sclerosis is a common neurological disor- side-effects of methylcobalamin overdoses can be rem- der characterised either by episodic patches of inflam- edied. mation and demyelination (relapsing remitting According to the invention, these objects can be evolution), or by a chronic progressive evolution, which reached by combining the methylcobalamin overdoses can occur anywhere in the central nervous system 10 with a simultaneous, separate or sequential administra- (CNS) almost always without any involvement in the tion of an antidepressant enhancing the serotonin level. peripheral nerves. The use of antidepressants which work by interfer- The pathogenesis of multiple sclerosis has not yet ing with the inactivation of neurotransmitters, in particu- been elucidated. Some believe that the pathogenesis lar noradrenaline and/or serotonin, for the treatment of involves local disruption of the blood brain barrier, a 15 multiple sclerosis or other demyelinating conditions has local immune and inflammatory response, with subse- already been disclosed in W096/1 1 009. In this interna- quent damage to myelin and hence to neurons. Others tional patent application, these antidepressants are suggest that an important aspect of the pathogenesis of used, in combination with precursors of said neuro- multiple sclerosis is a possible disturbance in vitamin transmitters, for compensating for the effects of nerve B12 (cobalamin) metabolism (see Reynolds EH, Linnell 20 damage caused by MS or the other demyelinating con- JC, Faludy JE - Multiple sclerosis associated with vita- ditions. Such a possible compensation of nerve damage min B12 deficiency. Arch. Neurol. 48: 808, 1991 and has for example been observed by Scott et al. (Scott, Reynolds EH, Bottiglieri T, Laundy M, Crellin RF, Kirfer CF Jr., Cashman N, Spitler LE. Experimental Allergic SG. Vitamin B12 metabolism in multiple sclerosis. Arch. Encephalitis ; Treatment with Drugs which alters CNS Neurol. 49:649, 1992). 25 Serotonin Levels. Journal of Immunopharmacology, Based on this suggestion, Kira J. et al (see Kira J, 4(3), 153-162 (1982-83)) in experimental allergic Tobimatsu S, Goto I. Vitamin B12 metabolism and mas- encephalitis (EAE) of Guinea pigs, which is an acute sive-dose methyl vitamin B12 therapy in Japanese autoimmune demyelinating disease caused artif ically by patients with multiple sclerosis. Internal Medicine Vol. immunization with Guinea pig myelin basic protein 33, No. 2, Febr. 1994), have examined the effects of 30 (GPBP). They found that this disease may more partic- high methyl vitamin B12 overdoses on motor disability ularly be due to an immune response directed against and multimodality evoked potential (MEP) abnormalities CNS serotonin receptors and that the effect of such a in six patients with chronic progressive MS. After a treat- serotonin receptor blockage could be compensated for ment for 6 months with oral daily doses of 60 mg, it by drugs, such as imipramine and tryptophan, which could be concluded that the MEP abnormalities reflect- 35 enhance CNS serotonin levels. If a serotonin receptor ing the demyelinating lesions in the afferent pathways blockage could be found in multiple sclerosis, such a were improved but the motor disability did not improve therapy could also be effective for the treatment of MS. clinically. A massive-dose methyl vitamin B12 therapy In WO 91/11009, it is further suggested to give a was therefore recommended as a possible adjunctive background course of vitamin B12, more particularly therapy to immunosuppressive treatments for multiple 40 cyanocobalamin or hydroxocobalamin, in daily amounts sclerosis. which may be for example the conventional daily The present inventor has also found that a therapy requirement for this vitamin. In the treatment examples, with vitamin B12 overdoses has a positive effect on the it was desirable for patients with chronic progressive reflexes of an MS patient indicating the occurrence of MS, to include an 8-10 week course of 1000 micro- myelin reconstruction. This effect could be achieved 45 grams of hydroxocobalamin (intra-muscular) per week with lower overdoses than the overdoses by Kira et al, at the start of the treatment with the antidepressant and for example with intramuscular (IM) doses of about then 1000 micrograms every ten days thereafter. Since 1 500 ng per week. However, even at these lower doses, it is generally known that a vitamin B1 2 deficiency leads strong side-effects of the vitamin B12 therapy were to demyelination of the nerves, this optional hydroxoco- observed comprising pains distributed over the entire so balamin background course was clearly intended to body, including pains in the feet, legs, shoulders, ears, have a positive effect on myelin reconstruction. teeth, etc. These pains occurred when administering The treatment proposed by the present invention is, hydroxocobalamin but extended and increased consid- on the contrary, first of all based on methylcobalamin erably when changing over to methylcobalamin admin- overdoses effective for achieving myelin reconstruction istration. Further, the motor ability did not improve by ss and thus for remedying nerve damage. Indeed, methyl- the vitamin B12 therapy, moreover, spasticity occasion- cobalamin appeared according to Kira et al (see supra) ally turned over in weakness and buckling reactions in to be much more effective for myelin reconstruction than the legs. hydroxocobalamin. As already mentioned hereinabove, 2 3 EP 0 835 660 A1 4 the side-effects observed by the inventor are however 3. Biological clock function of the pineal gland also much more pronounced for methylcobalamin than for hydroxocobalamin. According to the present inven- In the pineal gland (being one of the important tion, it has now been found surprisingly that a particular human biological clocks), tryptophan is converted, on group of the antidepressants, which have been sug- 5 the one hand, into vitamin B3 and, on the other hand, gested in W096/1 1009 for compensating for the effects into 5-hydroxotryptophan (5-HTP), which is further con- of nerve damage caused by MS or other demyelinating verted into serotonin. At night, the serotonin is con- conditions, was also very effective in remedying the verted into acetylserotonin and further into melatonin. side-effects of methylcobalamin overdoses, although The serotonin produced by day is an important activity, such overdoses do not lead to nerve damage but, on the w mobility and good mood promoter and immuno-protec- contrary, to nerve repair. tor whilst melatonin produced at night is an important This surprising effect can be explained on the basis recovery and protection hormone responsible for cell of a general hypothesis developed by the present inven- protection and regeneration and also for immuno-regu- tor with respect to the etiology of multiple sclerosis and lation. The working of the pineal gland biological clock is the observed side-effects of methylcobalamin over- 15 controlled by noradrenaline released at night by sym- doses. This hypothesis is based on a number of bio- patic nerve endings and acting on p-adrenergic recep- chemical working mechanisms which are already tors of the pineal gland (see Ozawa K, Segawa T. known per se and which are schematically indicated on Methyl B12 and the intracerebral signal transduction the scheme of the general hypothesis shown in the sole system. Methyl B12 Forum, "Methyl B12", Internet K.K., figure, some correlations and interactions between 20 Tokyo, 1993, pp.20-23). Ozawa et al. further explained these separated systems being described for the first the effects of methylcobalamin, which was known to be time by the present inventor. efficacious in the treatment of sleep-wake rhythm disor- ders, on the working of the biological clock as being 1. Vitamin B12 metabolism based on an acceleration or an improval of signal trans- 25 missions via p-receptors. So a lack of methylcobalamin Vitamin B12 is delivered by the food mainly in the leads to a hypo-sensitivity of the pineal gland and so to form of hydroxocobalamin. This hydroxocobalamin is a dysfunction of the biological clock. transferred to the cells through the intermediary of sev- An analogous explanation was given by Honma et eral transcobalamins and is taken up by these cells, in al (Honma K, Kohsaka M, Fukuda N, Morita M and particular by the cells of the CNS.
Load more

Recommended publications
  • Maturation and Development. Biological and Psychological Perspectives
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.46.4.375-b on 1 April 1983. Downloaded from Journal of Neurology, Neurosurgery, and Psychiatry 1983;46:375-376 definition by trained transcribers with an tumours in childhood. Book reviews interexaminer reliability of F = 0-81 fol- These volumes are much recommended Gilies de la Tourette Syndrome Volume 35 lowed by 2-way Anovas with blocking for to all neurosurgeons who wish to be of Advances in Neurology. Edited by subject pairs to compute F ratios for com- acquainted with the "state of play" in Arnold J Friedhoff and Thomas N Chase. paring the mean Z scores on each language paediatric neurosurgery. The editors are, (Pp 478; $58.90.) New York, Raven Press. function. This is incomprehensible as well however, very naive if they believe, as they 1982. as meaningless. It is impossible to find out suggest in their preface to volume 2, that it whether clonidine is really useful or not or may be "possible for paediatric This volume contains the proceedings of whether haloperidol does possess definite neurosurgeons throughout the entire world the 1981 New York symposium on advantages over other neuroleptics. to provide their knowledge and care to the Tourette syndrome. The 67 papers are This is the second major work on Gilles benefit of all children". At least 1000 mil- organised into 10 main sections, clinical de la Tourette's syndrome to appear in 4 lion of the world's population are provided and historical over-view, neuro-anatomy years, the first edited by the Shapiros, with very few neurosurgeons (for the and neuropathology, neurophysiology, Bruun, and Sweet.
    [Show full text]
  • Summary of Product Characteristics
    Package leaflet: Information for the patient Fluoxetine 20mg Capsules, hard fluoxetine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. •If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. What is in this leaflet 1. What Fluoxetine is and what it is used for 2. What you need to know before you take Fluoxetine 3. How to take Fluoxetine 4. Possible side effects 5. How to store Fluoxetine 6. Contents of the pack and other information 1. What Fluoxetine is and what it is used for The name of your medicine is Fluoxetine 20mg Capsules, hard. It contains the active substance fluoxetine. Fluoxetine belongs to a group of medicines called selective serotonin reuptake inhibitor (SSRI) antidepressants. Fluoxetine can be given to treat the following conditions: Adults: • Major depressive episodes • The symptoms of a condition called obsessive-compulsive disorder (OCD). • The eating disorder bulimia nervosa. This medicine is used alongside psychotherapy for the reduction of binge-eating and purging. Children and adolescents aged 8 years and above: • Moderate to severe major depressive disorder, if the depression does not respond to psychological therapy after 4-6 sessions. Fluoxetine should be offered to a child or young person with moderate to severe major depressive disorder only in combination with psychological therapy.
    [Show full text]
  • Ayahuasca: Spiritual Pharmacology & Drug Interactions
    Ayahuasca: Spiritual Pharmacology & Drug Interactions BENJAMIN MALCOLM, PHARMD, MPH [email protected] MARCH 28 TH 2017 AWARE PROJECT Can Science be Spiritual? “Science is not only compatible with spirituality; it is a profound source of spirituality. When we recognize our place in an immensity of light years and in the passage of ages, when we grasp the intricacy, beauty and subtlety of life, then that soaring feeling, that sense of elation and humility combined, is surely spiritual. The notion that science and spirituality are somehow mutually exclusive does a disservice to both.” – Carl Sagan Disclosures & Disclaimers No conflicts of interest to disclose – I don’t get paid by pharma and have no potential to profit directly from ayahuasca This presentation is for information purposes only, none of the information presented should be used in replacement of medical advice or be considered medical advice This presentation is not an endorsement of illicit activity Presentation Outline & Objectives Describe what is known regarding ayahuasca’s pharmacology Outline adverse food and drug combinations with ayahuasca as well as strategies for risk management Provide an overview of spiritual pharmacology and current clinical data supporting potential of ayahuasca for treatment of mental illness Pharmacology Terms Drug ◦ Term used synonymously with substance or medicine in this presentation and in pharmacology ◦ No offense intended if I call your medicine or madre a drug! Bioavailability ◦ The amount of a drug that enters the body and is able to have an active effect ◦ Route specific: bioavailability is different between oral, intranasal, inhalation (smoked), and injected routes of administration (IV, IM, SC) Half-life (T ½) ◦ The amount of time it takes the body to metabolize/eliminate 50% of a drug ◦ E.g.
    [Show full text]
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0065218A1 Migeon Et Al
    US 2005.0065218A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0065218A1 Migeon et al. (43) Pub. Date: Mar. 24, 2005 (54) UTILIZATION OF ALVERINE, ALONE OR IN (30) Foreign Application Priority Data COMBINATION WITH TRICYCLC ANTDEPRESSANT OR A SPECIFIC Jun. 13, 2003 (FR).............................................. O307176 SEROTONIN REUPTAKE INHIBITOR FOR Apr. 30, 2004 (FR).............................................. O404639 THE TREATMENT OF DEPRESSION Publication Classification (76) Inventors: Jacques Migeon, Seattle, WA (US); Frederic Revah, Paris (FR) (51) Int. C.7 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A61K 31/137 (52) U.S. Cl. .............................................................. 514/649 Correspondence Address: SESD LARDNER (57) ABSTRACT 3000 KSTREET NW WASHINGTON, DC 20007 (US) The present invention relates to the utilization of Alverine or its metabolites, alone or in combination with a tricyclic (21) Appl. No.: 10/866,079 antidepressant or a Specific Serotonin reuptake inhibitor, for the preparation of pharmaceutical compositions for the (22) Filed: Jun. 14, 2004 treatment of depression. 80 120 OO 8 O 6 O 40 20 t Excipicnts Alverine Alverine Alverine Imiprannine (1% methylcellulose) Citate Citrate Citrate 10 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg Patent Application Publication Mar. 24, 2005 Sheet 1 of 4 US 2005/0065218 A1 Excipients Alverine Alveline Alveline Inipramine (1% methylcellulose) Citrate Citrate Citrate 10 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg Fi gure US 2005/0065218A1 Imipramine 30 mg/kg Figure 2 Patent Application Publication Mar. 24, 2005 Sheet 3 of 4 US 2005/0065218A1 20 Vehicle + Whicule -- Averine Alvérine Vehicule + Alverine Vehicule imipramine 3 ring/kg it 3 mg/kg t- Impramine 10 mg/kg + 3 mg/kg Wellicule imipramine 10 mg/kg Vehicule 3 mg/kg Figure 3 Patent Application Publication Mar.
    [Show full text]
  • Long-Lasting Analgesic Effect of the Psychedelic Drug Changa: a Case Report
    CASE REPORT Journal of Psychedelic Studies 3(1), pp. 7–13 (2019) DOI: 10.1556/2054.2019.001 First published online February 12, 2019 Long-lasting analgesic effect of the psychedelic drug changa: A case report GENÍS ONA1* and SEBASTIÁN TRONCOSO2 1Department of Anthropology, Philosophy and Social Work, Universitat Rovira i Virgili, Tarragona, Spain 2Independent Researcher (Received: August 23, 2018; accepted: January 8, 2019) Background and aims: Pain is the most prevalent symptom of a health condition, and it is inappropriately treated in many cases. Here, we present a case report in which we observe a long-lasting analgesic effect produced by changa,a psychedelic drug that contains the psychoactive N,N-dimethyltryptamine and ground seeds of Peganum harmala, which are rich in β-carbolines. Methods: We describe the case and offer a brief review of supportive findings. Results: A long-lasting analgesic effect after the use of changa was reported. Possible analgesic mechanisms are discussed. We suggest that both pharmacological and non-pharmacological factors could be involved. Conclusion: These findings offer preliminary evidence of the analgesic effect of changa, but due to its complex pharmacological actions, involving many neurotransmitter systems, further research is needed in order to establish the specific mechanisms at work. Keywords: analgesic, pain, psychedelic, psychoactive, DMT, β-carboline alkaloids INTRODUCTION effects of ayahuasca usually last between 3 and 5 hr (McKenna & Riba, 2015), but the effects of smoked changa – The treatment of pain is one of the most significant chal- last about 15 30 min (Ott, 1994). lenges in the history of medicine. At present, there are still many challenges that hamper pain’s appropriate treatment, as recently stated by American Pain Society (Gereau et al., CASE DESCRIPTION 2014).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Designing Inhibitors Via Molecular Modelling Methods for Monoamine Oxidase Isozymes a and B Filiz Varnali Kadir Has Universit
    DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI M.S. in Computational Biology and Bioinformatics, Kadir Has University, 2012 Submitted to the Graduate School of Science and Engineering in partial fulfilment of the requirements for the degree of Master of Science in Computational Biology and Bioinformatics KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B Abstract In drug development studies, a large number of new drug candidates (leads) have to be synthesized and optimized by changing several moieties of the leads in order to increase efficacies and decrease toxicities. Each synthesis of these new drug candidates include multi-steps procedures. Overall, discovering a new drug is a very time-consuming and very costly works. The development of molecular modelling programs and their applications in pharmaceutical research have been formalized as a field of study known computer assisted drug design (CADD) or computer assisted molecular design (CAMD). In this study, using the above techniques, Monoamine Oxidase isozymes, which play an essential role in the oxidative deamination of the biogenic amines, were studied. Compounds that inhibit these isozymes were shown to have therapeutic value in a variety of conditions including several psychiatric and neurological as well as neurodegenerative diseases. First, a series of new pyrazoline derivatives were screened using molecular modelling and docking methods and promising lead compounds were selected, and proposed for synthesis as novel selective MAO-A or –B inhibitors.
    [Show full text]
  • Treatment of Social Phobia with Antidepressants
    Antidepressants for Social Phobia Treatment of Social Phobia With Antidepressants Franklin R. Schneier, M.D. This article reviews evidence for the utility of antidepressant medications in the treatment of social phobia. Monoamine oxidase inhibitors (MAOIs) were the first antidepressants shown to be effective © Copyrightfor social phobia, but 2001dietary restrictions Physicians and a relatively Postgraduate high rate of adverse effects Press, often relegate Inc. MAOIs to use after other treatments have been found ineffective. Reversible inhibitors of monoamine oxidase (RIMAs) hold promise as safer alternatives to MAOIs, but RIMAs may be less effective and are currently unavailable in the United States. Selective serotonin reuptake inhibitors (SSRIs), of which paroxetine has been the best studied in social phobia to date, have recently emerged as a first- line treatment for the generalized subtype of social phobia. The SSRIs are well tolerated and consis- tently have been shown to be efficacious in controlled trials. (J Clin Psychiatry 2001;62[suppl 1]:43–48) arly evidence that antidepressantsOne might personal have utility copy maypressant be printed treatment of other anxiety disorders, such as panic E in the treatment of social phobia emerged in the disorder and obsessive-compulsive disorder. In particular, 1970s when studies found efficacy for monoamine oxidase the high rate of comorbidity of anxiety disorders with de- inhibitors (MAOIs) in patient samples that included both pression3 makes treatment with antidepressants an efficient
    [Show full text]
  • Nialamide; SOCIETIES and LECTURES CORRECTION
    414 BRITISH MEDICAL JOURNAL 15 MAY 1971 care, and administration of health services. A. Clements, P. A. Connell, Patricia A. Crawford, G. A. Cupper, M. R. Dean, L. L. Dom- "It is, in short, medicine applied to a group SOCIETIES AND LECTURES bey, D. P. De Bono, J. P. Delamere, Gil- than to an individual patient." The lean P. Duncan, D. B. Dunger, C. E. G. Farqu- rather Br Med J: first published as 10.1136/bmj.2.5758.414 on 15 May 1971. Downloaded from statement adds that it is hoped that the pro- For attending lectures marked * a fee is charged or harson, Pamela C. Fenney, Daphne C. Fielding, a ticket is required. Applications should be made I. R. Fletcher, M. S. Fletcher, Po-Kai Fok, G. J. visional Faculty will be in a position to re- Frost, R. M. Galbraith, Elizabeth A. S. Galvin, first to the institution concerned. D. J. Giraldi, Jenifer I. Glover, B. A. Greenway, ceive applications from those wishing to be- Mary Griffin, J. F. Hamlyn, M. H. Hampton, come founder members later in the year. Monday, 17 May G. P. Harris, P. B. Harvey, A. C. Hillyard, Gillian M. M. Hodge, N. Holmes, Sheilagh M. Further announcements will be made. ABERDEEN UNIVERSITY.-At Medical Buildings, Hope, C. C. Hugh, Joanna E. Ide, Alison Ironside, Foresterhill, 5.30 p.m., dentj centennial lecture Keatley E. James, W. J. Jarrett, Celia A. Jenkins, by Sir Robert Bradlaw: Pigmentation. J. R. Jenner, P. D. Jones, C. L. Kennedy, N. D. Monoamine-oxidase Inhibitors INSTITUTE OF DERMATOLOGY.-4.30 p.m., Mr.
    [Show full text]
  • Insights Into the Mechanisms of Action Ofthe MAO Inhibitors Phenelzine and Tranylcypromine
    Insights into the Mechanisms of Action of the MAO Inhibitors Phenelzine and Tranylcypromine: A Review Glen B. Baker, Ph.D., Ronald T. Coutts, Ph.D., D.Sc., Kevin F. McKenna, M.D., and Rhonda L. Sherry-McKenna, B.Sc. Neurochemical Research Unit, Department of Psychiatry and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta Submitted: July 10, 1992 Accepted: October 7, 1992 Although the non-selective monoamine oxidase inhibitors phenelzine and tranylcypromine have been used for many years, much still remains to be understood about their mechanisms of action. Other factors, in addition to the inhibition of monoamine oxidase and the subsequent elevation of brain levels of the catecholamines and 5-hydroxytryptamine, may contribute to the overall pharma- cological profiles ofthese drugs. This review also considers the effects on brain levels of amino acids and trace amines, uptake and release of neurotransmitter amines at nerve terminals, receptors for amino acids and amines, and enzymes other than monoamine oxidase, including enzymes involved in metabolism of other drugs. The possible contributions of metabolism and stereochemistry to the actions of these monoamine oxidase inhibitors are discussed. Key Words: amino acids, monoamine oxidase, neurotransmitter amines, phenelzine, tranylcypromine, uptake Despite the fact that the non-selective monoamine oxidase nerve endings (Baker et al 1977; Raiteri et al 1977) and/or (MAO) inhibitors phenelzine (PLZ) and tranylcypromine may act as neuromodulators through direct actions on recep- (TCP) (see Fig. 1) have been used clinically for many years, tors for the catecholamines and/or 5-HT (Jones 1983; much remains to be learned about theirmechanisms ofaction.
    [Show full text]